HANISH ARNOLD C
HANISH ARNOLD C's purchase track record
HANISH ARNOLD C has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/20/2025 | DCOY | $4K | +6.4% | -28.6% | +13.9% |
| 6/3/2022 | DCOY | $5K | +18.9% | -60.2% | -0.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Cantor Fitzgerald upgrades Omeros to Overweight with $22 target. Cantor Fitzgerald upgraded Omeros to Overweight and set a $22 price target, citing potential for its transplant drug. The stock recently hit a five-year peak, reflecting growing investor interest. This move aligns with broader analyst optimism, as the average target price stands at $27.50.
Transaction History
| DCOY | ▲ Buy | Grant | 3,000 | $0 | 8/31/2026 | View on chart |
| OMER | ▲ Buy | Option Exercise | 2,500 | $40K | 8/27/2026 | View on chart |
| OMER | ▲ Buy | Option Exercise | 7,500 | $110K | 8/27/2026 | View on chart |
| OMER | ▼ Sell | Open Market | 5,000 | $95K | 8/27/2026 | View on chart |
| OMER | ▼ Sell | Open Market | 5,000 | $94K | 8/27/2026 | View on chart |
| OMER | ▼ Sell | Open Market | 5,000 | $93K | 8/26/2026 | View on chart |
| OMER | ▲ Buy | Option Exercise | 5,000 | $79K | 8/26/2026 | View on chart |
| DCOY | ▼ Sell | Open Market | 15 | $10 | 12/30/2025 | View on chart |
| DCOY | ▼ Sell | Open Market | 12 | $8 | 12/30/2025 | View on chart |
| DCOY | ▲ Buy | Open Market | 5,000 | $4K | 11/20/2025 | View on chart |
| OMER | ▲ Buy | Option Exercise | 5,000 | $27K | 5/22/2023 | View on chart |
| OMER | ▼ Sell | Open Market | 5,000 | $32K | 5/22/2023 | View on chart |
| DCOY | ▲ Buy | Grant | 1,440 | $0 | 1/3/2023 | View on chart |
| DCOY | ▲ Buy | Open Market | 28,000 | $5K | 6/3/2022 | View on chart |
| OMER | ▲ Buy | Option Exercise | 10,000 | $94K | 9/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
DCOY Reports Preclinical Data for Once-Weekly Dosing
Decoy Therapeutics released preclinical data supporting a once-weekly intranasal dosing schedule for its DCOY-CoV program. The company is also scheduled to present at The Small Cap Showcase investor conference. These updates provide context for the stock's current trading levels, which sit near significant support.
DCOY Reports Preclinical Data for Once-Weekly Dosing. Decoy Therapeutics released preclinical data supporting a once-weekly intranasal dosing schedule for its DCOY-CoV program. The company is also scheduled to present at The Small Cap Showcase investor conference. These updates provide context for the stock's current trading levels, which sit near significant support.